8 results
Tuberculosis Overview

10 million new M. tuberculosis infections/year
Facultative intracellular rod-shaped bacteria
Multidrug-resistant tuberculosis (MDR-TB) accounts for 4.6% of
90%) & develop latent ... Latent: Asymptomatic ... Presentation: Latent ... : Latent TB: • ... Tuberculin skin test
Tuberculosis Overview

10 million new M. tuberculosis infections/year
Facultative intracellular rod-shaped bacteria
Multidrug-resistant tuberculosis (MDR-TB) accounts for 4.6% of
90%) & develop latent ... Latent: Asymptomatic ... Presentation: Latent ... : Latent TB: • ... Tuberculin skin test
IDSA Recommendations for Preventing Human Papillomavirus Infections and Cervical Cancer Screening for Women with in HIV-AIDS
Recommendations
IDSA Recommendations ... or been newly diagnosed ... following initial diagnosis ... #Prevention #Treatment ... infections #HIVAIDS #pharmacology
The Stages of Syphilis 

Primary Syphilis 
- The chancre lesion is the hallmark of primary syphilis.
Without treatment ... - Early latent ... - Late Latent ... - Late latent patients ... #Tertiary #Diagnosis
IDSA Recommendations for Treating Mycobacterium Tuberculosis Infection and Disease in HIV-AIDS
Treating LTBI (to prevent TB disease)
Indications:
IDSA Recommendations ... for active or latent ... and molecular diagnostic ... #Prevention #Treatment ... infections #HIVAIDS #pharmacology
IDSA Recommendations for Preventing and Managing Microsporidiosis in HIV-AIDS
Preventing Chronic Microsporidiosis:
 • Because chronic microsporidiosis occurs
IDSA Recommendations ... bieneusi: • The best ... treatment option ... #Prevention #Treatment ... infections #HIVAIDS #pharmacology
IDSA Recommendations for Treating Cytomegalovirus Infections in HIV-AIDS
Preventing CMV Disease:
 • CMV end-organ disease is best
IDSA Recommendations ... Disease: • CMV end-organ ... disease is best ... #Prevention #Treatment ... infections #HIVAIDS #pharmacology
IDSA Recommendations for Treating Treponema pallidum Infections (Syphilis) to Prevent Disease in HIV-AIDS
Early Stage (Primary, Secondary,
Secondary, and Early-Latent ... 1 dose (BII) Late-Latent ... (>1 year) or Latent ... #Prevention #Treatment ... infections #HIVAIDS #pharmacology